NCT04703686 2026-03-16
Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy
The Lymphoma Academic Research Organisation
Phase 2 Completed
Clinical Trials
21 trialsNCT03332017 2026-02-18
ROSEWOOD
BeOne Medicines
Phase 2 Completed
NCT02896582 2026-01-14
LyMa101
The Lymphoma Academic Research Organisation
Phase 2 Completed
NCT02666898 2025-11-26
ICLL07GAI
French Innovative Leukemia Organisation
Phase 2 Completed
NCT05105841 2025-10-15
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
AbbVie
Phase 2 Completed
NCT04880863 2025-03-03
NT-NAP-102-1
NeoTX Therapeutics Ltd.
Phase 2 Completed
NCT03787264 2024-12-30
CLL2-BAAG
German CLL Study Group
Phase 2 Completed
NCT04189588 2023-10-06
versus
TerSera Therapeutics LLC
Phase 2 Completed
NCT02962401 2023-08-29
RemodelWM3
French Innovative Leukemia Organisation
Phase 2 Completed
NCT02758665 2023-01-17
CLL2-GiVe
University of Ulm
Phase 2 Completed
NCT03276468 2023-01-10
Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas
The Lymphoma Academic Research Organisation
Phase 2 Completed
NCT02968563 2022-01-21
Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Gilead Sciences
Phase 2 Completed
NCT02736617 2022-01-05
Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma
OHSU Knight Cancer Institute
Phase 2 Completed
NCT02983617 2021-12-21
Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)
Gilead Sciences
Phase 2 Completed
NCT03755947 2021-02-02
Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia
Grupo Cooperativo de HemopatÃas Malignas
Phase 2 Completed
NCT02320487 2020-02-11
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Genentech, Inc.
Phase 2 Completed
NCT02071225 2020-02-07
A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia
Hoffmann-La Roche
Phase 2 Completed
NCT01414855 2018-04-25
A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)
Genentech, Inc.
Phase 2 Completed
NCT01414205 2017-04-17
A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE)
Genentech, Inc.
Phase 2 Completed
NCT01868893 2017-04-17
An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Genentech, Inc.
Phase 2 Completed
NCT00576758 2014-08-19
GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma
Hoffmann-La Roche
Phase 2 Completed